Gonçalo C.
- Country
- Portugal
- Department
- N/A
Research Overview
- Randomized Study of Cagrilintide + Semaglutide Combination vs Semaglutide Monotherapy for Weight Loss in Adults with Obesity (± Type 2 Diabetes)
- Phase 2 Evaluation of Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
- Phase III Randomized Controlled Trial Evaluating Tinengotinib Versus Physician's Choice in FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Refractory Cholangiocarcinoma
Data & Insights
Has run more than one trial at 59 of 566 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating patients with cholangiocarcinoma, focusing particularly on advanced and refractory cases of this rare biliary tract cancer.
- Advanced Biliary Tract Malignancies
- Treatment-Resistant Cholangiocarcinoma
- Targeted Cancer Therapies
Expertise extends to managing complex cases that have progressed after prior treatments.
Molecular Oncology
The investigator focuses on FGFR-altered cancers, particularly exploring novel therapeutic approaches for patients with specific molecular alterations.
- FGFR Pathway Targeting
- Molecular Profiling
- Personalized Treatment Approaches
Specializes in developing treatment strategies for patients with specific genetic alterations.
Treatment Innovation
Active involvement in evaluating novel therapeutic agents including futibatinib and tinengotinib for treating advanced biliary tract cancers.
- Novel Drug Development
- Treatment-Resistant Cancers
- Alternative Treatment Strategies
Focuses on developing new treatment options for patients who have exhausted standard therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.